The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PMV Pharmaceuticals, Inc
National Institutes of Health Clinical Center (CC)
Tizona Therapeutics, Inc
Essen Biotech
IDEAYA Biosciences
Takeda
Eli Lilly and Company
Astellas Pharma Inc
Turnstone Biologics, Corp.
Intensity Therapeutics, Inc.
Carisma Therapeutics Inc
Eli Lilly and Company
Astellas Pharma Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Ikena Oncology
Ikena Oncology
GeneMedicine Co., Ltd.
OHSU Knight Cancer Institute
Atreca, Inc.
Corvus Pharmaceuticals, Inc.
Fate Therapeutics
Kineta Inc.
M.D. Anderson Cancer Center
Oncorus, Inc.
Fate Therapeutics
Silverback Therapeutics
Incyte Corporation
Western Regional Medical Center
Seagen Inc.
Western Regional Medical Center